我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1973
进行中（未招募）
1
10.0%
已完成
5
50.0%
尚未招募
招募中
3
30.0%
暂无批准数据
- Qatar University researchers highlight Apabetalone's potential as an epigenetic therapy for treating various chronic diseases by targeting gene expression. - Apabetalone, a unique inhibitor with FDA breakthrough therapy designation (excluding oncology), impacts multiple biological functions involved in disease development. - Preclinical studies suggest Apabetalone's efficacy in cardiovascular, renal, neurological, viral, and cancer disorders, warranting further investigation in clinical trials. - The research underscores the importance of epigenetic treatments in regulating gene transcription and improving cell communication for enhanced health outcomes.
